Latest News

Date Title Topic
31 Oct 2016 NICE Recommends Osimertinib for Advanced EGFR T790M Mutation-Positive NCSLC Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
28 Oct 2016 Media Alert: ESMO Symposium on Immuno-Oncology 2016 Cancer Immunology and Immunotherapy
28 Oct 2016 FDA Approves Pembrolizumab for First-Line Treatment of Metastatic NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
27 Oct 2016 EMA Recommends a Change to the Terms of the Marketing Authorisation for Arsenic Trioxide Haematologic malignancies - Anticancer agents & Biologic therapy
26 Oct 2016 Off-Label Drug Coverage in Oncology Bioethics, legal and economic issues - Anticancer agents & Biologic therapy
24 Oct 2016 FDA Grants Accelerated Approval to New Treatment for Advanced STS Sarcomas - Anticancer agents & Biologic therapy
24 Oct 2016 FDA Modifies Indication for Erlotinib in NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
21 Oct 2016 2016 Nobel Prize in Physiology or Medicine Basic science
20 Oct 2016 FDA Approves Atezolizumab for Metastatic NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
19 Oct 2016 EMA Adopts a New Indication for Nivolumab Haematologic malignancies - Cancer Immunology and Immunotherapy
Video Highlights
18 Oct 2016 Withdrawal of the Marketing Authorisation Application for Cediranib Gynaecologic malignancies - Anticancer agents & Biologic therapy
17 Oct 2016 EMA Recommends Granting a Conditional Marketing Authorisation for Venetoclax Haematologic malignancies - Anticancer agents & Biologic therapy
Webcasts
11 Oct 2016 ESMO 2016 Press Release: Best of ESMO 2016 Congress